International Journal of Coronaviruses

ISSN: 2692-1537

IJCV

Ongoing Special Issue
 
Special Issue On - "Multi-Omics approach to understand Covid-19"
Theme of the Issue: "SARS-CoV-2: Omics' analysis in Covid-19"
 
This theme or title is dedicated to the analysis of the data (bioinformatics), genes (genomics), proteins (proteomics), the transcripted (transcriptomic), metabolites (metabolomics) in Covid-19.

Special Issue By - Dr. Raul Isea
 
This special issue calls for original papers with important and novel contributions related to – “Multi-Omics approach to understand Covid-19
 

Topics of interests include

  • Omics data analysis
  • Bioinformatics analysis
  • Genomic analysis
  • Proteomics analysis
  • Transcriptomics analysis
  • Metabolomics analysis
  • Microarray analysis

Reviews which include the comparative view, Original research papers as well as short communications and letters on new developments and applications are welcome and are to be written in Standard English. Formatting of the manuscript with headings and Subheadings is necessary and views are to be presented clearly. New approaches are mainly in interest.


Metrics:

  • Acceptance period: 14 days from the submitted date
  • People involved: Dr. Raul Isea- Editor

The importance and need for this special issue:

We are happy to invite you to submit a manuscript for International Journal of Coronavirus in the Special Issue titled "Multi-Omics approach to understand Covid-19".

We welcome all the original research and up-to-data review articles on the application of OMIC tools to help combat SARS-CoV-2.

The OMICS studies such as genomics, proteomic, peptidomics,transcriptomics, metabolomics, lipidomics, and also bioinformatics tool, are welcome in this Special Issue. These technologies allows us to discover, for example, new drugs and vaccines targets to combat Covid-19.

Submission Instructions: All submissions will undergo peer review and accepted articles will be published in the International Journal of Coronaviruses (ISSN: 2692-1537).